SELLAS Life Sciences/$SLS
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About SELLAS Life Sciences
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
- Ticker
- $SLS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- -
- Headquarters
- New York, United States
- Website
- sellaslifesciences.com
SLS Metrics
BasicAdvanced
$1.7B
-
-$0.21
2.49
-
Price and volume
Market cap
$1.7B
Beta
2.49
52-week high
$15.88
52-week low
$1.39
Average daily volume
6.7M
Financial strength
Current ratio
18.827
Quick ratio
18.278
Long term debt to equity
0.001
Total debt to equity
0.005
Profitability
Management effectiveness
Return on assets (TTM)
-23.30%
Return on equity (TTM)
-39.63%
Valuation
Price to book
12.35
Price to tangible book (TTM)
12.52
Price to free cash flow (TTM)
-45.294
Free cash flow yield (TTM)
-2.21%
Free cash flow per share (TTM)
-0.186
Growth
Earnings per share change (TTM)
-33.89%
3-year earnings per share growth (CAGR)
-48.44%
What the Analysts think about SLS
Analyst ratings (Buy, Hold, Sell) for SELLAS Life Sciences stock.
Analyst projections of the future price of SELLAS Life Sciences stock.
Bulls say / Bears say
REGAL has reached its pre-set 80-event trigger, and SELLAS expects topline results this quarter; a positive overall-survival result could support a BLA submission. (SELLAS Life Sciences)
In a Phase 1 lymphoma study, SLS009 produced a 14.7% response rate overall and 36.4% among 11 patients with peripheral T-cell lymphoma, with no unexpected toxicities reported. This gives SELLAS a clinical signal beyond GPS. (OncLive)
SLS009 has advanced into an 80-patient Phase 2 trial in newly diagnosed AML, with 28 patients enrolled by August and topline data expected in Q4 2026. Positive data could broaden its potential use in AML. (SELLAS Life Sciences)
The 80th-death trigger starts the final analysis; SELLAS has not disclosed whether GPS improved overall survival. Its pivotal investment case still depends on an unreported clinical result. (SELLAS Life Sciences)
SELLAS had no product revenue in the first half of 2026, used $16.4 million in operating cash and reported an $18 million net loss. It expects continuing losses and says it will need more funding to reach profitability. (SEC)
The share count rose from 153.1 million at year-end 2025 to 201.9 million by June 2026, largely after warrant exercises. A $150 million at-the-market share-sale facility also remains available, creating further dilution risk. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 29 Oct 2026.
SLS Financial Performance
Revenues and expenses
SLS Earnings Performance
Company profitability
Upcoming events
No upcoming events
SLS News
AllArticlesVideos
Funds containing SLS
Fund name | Fund size | $SLS weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | $5B | 0.06% |
SPDR Russell 2000 US Small Cap£R2SC | $5B | 0.06% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | $2.7B | 0.02% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | $2.7B | 0.02% |
Xtrackers MSCI World Small Cap$XSWC | $183M | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.